Put companies on watchlist
Biotest AG
ISIN: DE0005227235
WKN: 522723
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Biotest AG · ISIN: DE0005227235 · EQS - Company News (132 News)
Country: Germany · Primary market: Germany · EQS NID: 2030101
14 November 2024 10:14AM

Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million


EQS-News: Biotest AG / Key word(s): 9 Month figures
Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million

14.11.2024 / 10:14 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE


Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million

 

  • Product sales and toll manufacturing increased by 13,7% to € 414 million, in part thanks to the growth of Yimmugo®
  • Adjusted EBIT was maintained at previous year's level as growing core business gradually replaces earnings  from technology transfer and development services
  • Biotest submitted initial marketing authorization application for its Fibrinogen Concentrate (BT524) following the decentralized procedure for approval in Germany, Austria and Spain
  • Guidance for revenue, cash flow and ROCE corrected
  • EBIT guidance remains unchanged

 

Dreieich, Germany, November 14, 2024. The Biotest Group generated sales of € 522.7 million in the first nine months of the financial year 2024. This corresponds to an increase of 4.5% compared to the same period of the previous year (€ 500.3 million). Revenue from products and toll manufacturing increased by € 49.9 million or 13.7%, to € 414.4 million. In addition, revenue from technology disclosure and development services for Grifols, S.A. as part of the technology transfer and license agreement amounted to € 108.3 million, compared to € 135.4 million in the same period of the previous year.

The new intravenous immunoglobulin Yimmugo® had a particularly positive impact, with sales increasing by € 25.5 million to € 41.6 million.

Group EBIT decreased to € 71.1 million in the first nine months of 2024 from € 125.4 million in the same period of 2023. This development is largely due to the contribution from technology disclosure and development services as part of the technology and license agreement with Grifols, S.A. which reduced to € 87.3 million, compared to € 112.3 million.

At € 37.0 million, adjusted EBIT, which reflects operating performance excluding exceptional items, was above the previous year’s level (€ 34.8 million).

The financial result for the first nine months of the current financial year improved to € -26.6 million (previous year: € -29.3 million). This development is mainly due to the € 4.9 million decrease in interest expenses. Tax expenses increased by € 7.0 million to € 14.6 million compared to the previous year.

As a result of the factors described above, earnings after tax (EAT) for the Biotest Group fell to € 29.9 million in the first three quarters of the 2024 financial year, compared to € 88.4 million in the same period of the previous year. This corresponds to earnings per ordinary share of € 0.75, compared with € 2.22 in the same period of the previous year.

Biotest submitted the initial marketing authorization application for its fibrinogen concentrate (BT524) to the Paul-Ehrlich-Institute, following the decentralized procedure for approval in Germany, Austria and Spain. A first marketing authorization is expected for mid-2025.

 

Outlook:

The Board of Management currently expects a revenue increase in the low single-digit percentage range for the 2024 financial year compared to 2023. This includes revenues from technology disclosure and from development services for Grifols, S.A. Previously, an increase in the high single-digit percentage range had been expected. The ongoing conflict in the Middle East poses significant risks to revenue and earnings. Economic instability in the region could lead to decreasing sales figures and may impact our financial performance. Additionally, supply chain disruptions may result in delays and increased costs.

The return on capital employed (ROCE) for the 2024 financial year is to be corrected to the range of 5-8% and the cash flow from operating activities to a negative mid-double-digit million range. Previously, a slightly improved ROCE compared to the 2023 financial year (12.3% as of December 31, 2023) and a positive cash flow from operating activities significantly above the previous year's level have been expected (€ -2.7 million as of December 31, 2023). Measures to improve the cash flow have already been initiated.

The Board of Management expects an operating result (EBIT) in a range between € 80 million and € 100 million for 2024.

The nine-month report is available on the company's website under Quarterly Reports (biotest.com).

 

 

About Biotest

Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com).

 

 

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

 

PR contact

Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

 

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



14.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-767
E-mail: ir@biotest.com
Internet: www.biotest.com
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2030101

 
End of News EQS News Service

2030101  14.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2030101&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Biotest AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.